INHIBACE 5 MG — DIN 01911481
CILAZAPRIL (CILAZAPRIL MONOHYDRATE) : 5 MG · CHEPLAPHARM ARZNEIMITTEL GMBH · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is INHIBACE?
INHIBACE 5 MG contains CILAZAPRIL (CILAZAPRIL MONOHYDRATE) : 5 MG. It is listed in the Health Canada Drug Product Database under DIN 01911481, held by CHEPLAPHARM ARZNEIMITTEL GMBH, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 19-Aug-2019. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is INHIBACE used for?
Treatment of mild to moderate essential hypertension and congestive heart failure (as adjunctive therapy with digitalis and/or diuretics).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Cilazapril cost around the world?
Cilazapril is listed on 10 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Austria publishes a KVP (Kassenverkaufspreis); Belgium publishes a public; Czechia publishes a max producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Czechia | max producer price (ex-factory) | 2 | 5 | CZK███.██ |
| Austria | KVP (Kassenverkaufspreis) | 4 | 4 | EUR███.██ |
| Saudi Arabia | public | 3 | 3 | SAR███.██ |
| South Africa | single exit price | 2 | 3 | ZAR███.██ |
| Greece | producer price (ex-factory) | 2 | 2 | EUR███.██ |
| Italy | prezzo al pubblico (classe A) | 2 | 2 | EUR███.██ |
| Morocco | PPV (public price) | 1 | 2 | MAD███.██ |
| Belgium | public | 1 | 1 | EUR███.██ |
| Spain | PVP con IVA (public price) | 1 | 1 | EUR███.██ |
| Hungary | producer price (ex-factory) | 1 | 1 | HUF███.██ |
24 pack listings across 19 brand entries and 8 price bases, refreshed 05 Sep 2026. Ranges span every Cilazapril pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Cilazapril in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
10 holders have a Canadian DIN containing Cilazapril, across 33 DINs, of which 6 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| MYLAN PHARMACEUTICALS ULC | 3 | 3 | MYLAN-CILAZAPRIL | Sourceable in Canada |
| APOTEX INC | 3 | 2 | APO-CILAZAPRIL | Sourceable in Canada |
| CHEPLAPHARM ARZNEIMITTEL GMBH | 2 | 1 | INHIBACE | Sourceable in Canada |
| COBALT PHARMACEUTICALS COMPANY | 6 | 0 | CILAZAPRIL, CO CILAZAPRIL | No marketed DIN |
| TEVA CANADA LIMITED | 6 | 0 | NTP-CILAZAPRIL, TEVA-CILAZAPRIL | No marketed DIN |
| DOMINION PHARMACAL | 3 | 0 | DOM-CILAZAPRIL | No marketed DIN |
| PHARMASCIENCE INC | 3 | 0 | PMS-CILAZAPRIL | No marketed DIN |
| PHARMEL INC | 3 | 0 | PHL-CILAZAPRIL | No marketed DIN |
| SANIS HEALTH INC | 3 | 0 | CILAZAPRIL | No marketed DIN |
| HOFFMANN-LA ROCHE LIMITED | 1 | 0 | INHIBACE TAB 1MG | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 5 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | Not explicitly detailed in provided text (mentions bottles of 100 in prompt example, but text only lists strengths). |
| Storage | Not specified in the provided text (refer to Storage and Stability section 32, not included in snippet). |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Cilazapril |
|---|---|
| ATC code | C09AA08 |
| AHFS class | 24:32.04 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 01911481 |
|---|---|
| DIN (unpadded, as printed on some documents) | 1911481 |
| Brand name | INHIBACE |
| Generic / active ingredient | CILAZAPRIL (CILAZAPRIL MONOHYDRATE) : 5 MG |
| Market authorization holder | CHEPLAPHARM ARZNEIMITTEL GMBH |
| Health Canada schedule | Prescription |
| ATC code | C09AA08 |
| ATC anatomical main group | C — Cardiovascular system |
| ATC therapeutic subgroup | C09AA |
| Current status | MARKETED |
| Status date | 19-Aug-2019 |
| Original market date | 1993-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Hypertension: normally used if diuretics/beta-blockers ineffective. CHF: adjunctive therapy with digitalis/diuretics. Start under close medical supervision, especially in at-risk patients.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to cilazapril; history of ACEI-related angioedema; anuria; ascites; pregnancy; nursing; concomitant use with aliskiren in diabetes/renal impairment; neprilysin inhibitors.
Warnings and precautions
Serious Warning: Fetal/neonatal morbidity and mortality. Risk of angioedema, severe hypotension (especially first-dose), neutropenia/agranulocytosis, and hyperkalemia.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
6 of 33 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-CILAZAPRIL | 5 MG | TABLET | APOTEX INC | MARKETED | 02291150 |
| APO-CILAZAPRIL | 2.5 MG | TABLET | APOTEX INC | MARKETED | 02291142 |
| MYLAN-CILAZAPRIL | 2.5 MG | TABLET | MYLAN PHARMACEUTICALS ULC | MARKETED | 02283786 |
| MYLAN-CILAZAPRIL | 5.0 MG | TABLET | MYLAN PHARMACEUTICALS ULC | MARKETED | 02283794 |
| MYLAN-CILAZAPRIL | 1 MG | TABLET | MYLAN PHARMACEUTICALS ULC | MARKETED | 02283778 |
| APO-CILAZAPRIL | 1 MG | TABLET | APOTEX INC | DORMANT | 02291134 |
| CILAZAPRIL | 5.0 MG | TABLET | COBALT PHARMACEUTICALS COMPANY | CANCELLED PRE MARKET | 02345234 |
| CILAZAPRIL | 1.0 MG | TABLET | COBALT PHARMACEUTICALS COMPANY | CANCELLED PRE MARKET | 02345218 |
| CILAZAPRIL | 2.5 MG | TABLET | COBALT PHARMACEUTICALS COMPANY | CANCELLED PRE MARKET | 02345226 |
| CILAZAPRIL | 1 MG | TABLET | SANIS HEALTH INC | CANCELLED POST MARKET | 02350963 |
2 · Same class — other molecules in ATC C09AA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Ramipril | ACH-RAMIPRIL · ACT RAMIPRIL · AG-RAMIPRIL · ALTACE · +37 more | 171 | 55 | Yes |
| Perindopril | AG-PERINDOPRIL · AG-PERINDOPRIL ERBUMINE · APO-PERINDOPRIL · APO-PERINDOPRIL ARGININE · +20 more | 81 | 54 | Yes |
| Enalapril | ACT ENALAPRIL · APO-ENALAPRIL · AVA-ENALAPRIL · DOM-ENALAPRIL · +21 more | 100 | 36 | Yes |
| Trandolapril | APO-TRANDOLAPRIL · AURO-TRANDOLAPRIL · MAVIK · MYLAN-TRANDOLAPRIL · +4 more | 40 | 25 | Yes |
| Lisinopril | ACT LISINOPRIL · APO-LISINOPRIL · APO-LISINOPRIL TABLET (TYPE P) - 10MG · APO-LISINOPRIL TABLET (TYPE P) - 20MG · +28 more | 99 | 15 | Yes |
| Captopril | APO-CAPTO TAB 100MG · APO-CAPTO TAB 12.5MG · APO-CAPTO TAB 25MG · APO-CAPTO TAB 50MG · +41 more | 77 | 9 | Yes |
| Cilazapril | APO-CILAZAPRIL · CILAZAPRIL · CO CILAZAPRIL · DOM-CILAZAPRIL · +7 more | 33 | 6 | Yes |
| Fosinopril | APO-FOSINOPRIL · AVA-FOSINOPRIL · FOSINOPRIL · FOSINOPRIL TABLETS · +14 more | 32 | 6 | Yes |
| Quinapril | ACCUPRIL 5MG TAB · ACCUPRIL TAB 10MG · ACCUPRIL TAB 20MG · ACCUPRIL TAB 40MG · +7 more | 32 | 6 | Yes |
| Benazepril | BENAZEPRIL · LOTENSIN 10MG · LOTENSIN 20MG · LOTENSIN 5MG · +1 more | 9 | 3 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is INHIBACE called?
The same molecule, Cilazapril, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Inhibace Plus | Latin | Czechia, South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.